NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2026)

NewAmsterdam Pharma has reported Other Non-Current Liabilities for 5 years, with the latest figure at $50.2 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 113.53% year-over-year to $50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.2 million (up 113.53% YoY) and the FY2025 annual result came in at $57.3 million, down 30.42% from the prior year.
• Other Non-Current Liabilities fell to $50.2 million in Q1 2026 per NAMS's latest filing, from $57.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $82.3 million in Q4 2024 and troughed at $7195.8 in Q4 2022.
• A 5-year average of $27.9 million and a median of $19.9 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 162752.0% in 2024, then sank 30.42% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $7195.8 in 2022, then soared by 108129.73% to $7.8 million in 2023, then jumped by 956.91% to $82.3 million in 2024, then tumbled by 30.42% to $57.3 million in 2025, then decreased by 12.3% to $50.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $50.2 million, $57.3 million, and $44.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.